This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-24 (Canceled)

Claim 25 (Currently Amended) ~~The~~ An isolated polypeptide ~~of Claim 22~~ having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42);

(b) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide; or~~

~~(e)~~(c) the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209492;

wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claim 26 (Currently Amended) ~~The~~ An isolated polypeptide ~~of Claim 22~~ having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42;

(b) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide; or~~

~~(e)~~(c) the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209492;

wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claim 27 (Currently Amended) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42);

(b) the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide;

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 18 (SEQ ID NO:42), lacking its associated signal peptide; or~~

~~(e)~~(c) the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209492;

wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claim 28 (Currently Amended) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide shown in Figure 18 (SEQ ID NO:42), wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claims 29-31 (Canceled)

Claim 32 (Previously Presented) The isolated polypeptide of Claim 27 comprising the amino acid sequence of the polypeptide encoded by the full length coding sequence of the cDNA deposited under ATCC accession number 209492.

Claim 33 (Currently Amended) A chimeric polypeptide comprising a polypeptide according to Claim ~~22~~ 25 fused to a heterologous polypeptide.

Claim 34 (Previously Presented) The chimeric polypeptide of Claim 33, wherein said heterologous polypeptide is an epitope tag or an Fc region of an immunoglobulin.

Please add the following new claims:

Claim 35 (New) An isolated polypeptide comprising a sequence that encodes a polypeptide of SEQ ID NO: 42 with conservative amino acid substitutions, wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claim 36 (New) An isolated polypeptide comprising a sequence that encodes a polypeptide of SEQ ID NO: 42 with 0-12 amino acid additions, deletions, or substitutions, wherein the polypeptide inhibits neoplastic growth in tumor cells.

Claim 37 (New) A method of using the polypeptide of Claim 25 to inhibit neoplastic growth of tumor cells comprising administering to a cell, cell population, tissue, organ, or organism a therapeutically effective amount of said polypeptide or a pharmaceutically acceptable variant thereof.